Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Durvalumab |
Synonyms | |
Therapy Description |
Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, and in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Durvalumab | Imfinzi | MEDI4736 | Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 115 | Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, and in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | transitional cell carcinoma | predicted - sensitive | Durvalumab | Phase Ib/II | Actionable | In a Phase I/II trial, treatment with Imfinzi (durvalumab) resulted in an overall response rate (ORR) of 17.8% (34/191) in advanced urothelial carcinoma patients with an ORR of 27.6% (27/98) in patients with high PD-L1 (CD274) expression and 5.1% (4/79) in patients with low or negative PD-L1 (CD274), and similar complete response rates between the two groups (PMID: 28817753; NCT01693562). | 28817753 |
MSH2 negative | endometrial cancer | sensitive | Durvalumab | Guideline | Actionable | Imfinzi (durvalumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org). | detail... 35690222 |
MSH2 negative | endometrial cancer | sensitive | Durvalumab | Phase II | Actionable | In a Phase II trial (PHAEDRA), Imfinzi (durvalumab) treatment resulted in superior objective tumor response rate (47%, 17/36, 6 complete responses, 11 partial responses (PR) vs 3%, 1/35, 1 PR) and median progression-free survival (8.3 vs 1.8 mo) in patients with mismatch repair deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) advanced endometrial cancer compared to mismatch repair proficient patients (PMID: 34103352; NCT03015129). | 34103352 |
MSH2 negative | endometrial cancer | sensitive | Durvalumab | Guideline | Actionable | Immune checkpoint inhibitor monotherapy including Imfinzi (durvalumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). | 36696825 detail... |
ALK rearrange | lung non-small cell carcinoma | no benefit | Durvalumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Imfinzi (durvalumab), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694). | 27225694 |
ALK rearrange | lung non-small cell carcinoma | no benefit | Durvalumab | Guideline | Actionable | Immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), and Imfinzi (durvalumab) are not indicated for use as subsequent therapy in non-small cell lung cancer patients with ALK rearrangement (NCCN.org). | detail... |
MSH6 negative | endometrial cancer | predicted - sensitive | Durvalumab | Guideline | Actionable | Imfinzi (durvalumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org). | detail... 35690222 |
MSH6 negative | endometrial cancer | predicted - sensitive | Durvalumab | Phase II | Actionable | In a Phase II trial (PHAEDRA), Imfinzi (durvalumab) treatment resulted in superior objective tumor response rate (47%, 17/36, 6 complete responses, 11 partial responses (PR) vs 3%, 1/35, 1 PR) and median progression-free survival (8.3 vs 1.8 mo) in patients with mismatch repair deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) advanced endometrial cancer compared to mismatch repair proficient patients (PMID: 34103352; NCT03015129). | 34103352 |
MSH6 negative | endometrial cancer | predicted - sensitive | Durvalumab | Guideline | Actionable | Immune checkpoint inhibitor monotherapy including Imfinzi (durvalumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). | 36696825 detail... |
MLH1 negative | endometrial cancer | sensitive | Durvalumab | Phase II | Actionable | In a Phase II trial (PHAEDRA), Imfinzi (durvalumab) treatment resulted in superior objective tumor response rate (47%, 17/36, 6 complete responses, 11 partial responses (PR) vs 3%, 1/35, 1 PR) and median progression-free survival (8.3 vs 1.8 mo) in patients with mismatch repair deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) advanced endometrial cancer compared to mismatch repair proficient patients (PMID: 34103352; NCT03015129). | 34103352 |
MLH1 negative | endometrial cancer | sensitive | Durvalumab | Guideline | Actionable | Immune checkpoint inhibitor monotherapy including Imfinzi (durvalumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). | 36696825 detail... |
MLH1 negative | endometrial cancer | sensitive | Durvalumab | Guideline | Actionable | Imfinzi (durvalumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org). | 35690222 detail... |
PMS2 negative | endometrial cancer | sensitive | Durvalumab | Phase II | Actionable | In a Phase II trial (PHAEDRA), Imfinzi (durvalumab) treatment resulted in superior objective tumor response rate (47%, 17/36, 6 complete responses, 11 partial responses (PR) vs 3%, 1/35, 1 PR) and median progression-free survival (8.3 vs 1.8 mo) in patients with mismatch repair deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) advanced endometrial cancer compared to mismatch repair proficient patients (PMID: 34103352; NCT03015129). | 34103352 |
PMS2 negative | endometrial cancer | sensitive | Durvalumab | Guideline | Actionable | Imfinzi (durvalumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org). | detail... 35690222 |
PMS2 negative | endometrial cancer | sensitive | Durvalumab | Guideline | Actionable | Immune checkpoint inhibitor monotherapy including Imfinzi (durvalumab) is included in the Pan-Asian Guidelines Adaptation (PAGA) for patients with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or metastatic endometrial cancer who have failed prior platinum-based chemotherapy (PMID: 36696825; ESMO.org). | 36696825 detail... |
CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Durvalumab | Phase II | Actionable | In a Phase II trial (ATLANTIC), Imfinzi (durvalumab) treatment resulted in superior objective response rate in non-small cell lung cancer patients with 25% or more tumor cells expressing CD274 (PD-L1) compared to patients with CD274 (PD-L1) expression in less than 25% of tumor cells, in both the cohort harboring EGFR and ALK mutations (12.2% vs 3.6%) and the EGFR and ALK wild-type cohort (16.4% vs 7.5%) (PMID: 29545095; NCT02087423). | 29545095 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04441138 | Phase II | Durvalumab | Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC (ESR1814205) | Recruiting | USA | 0 |
NCT03148327 | Phase Ib/II | Durvalumab | Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy | Active, not recruiting | USA | AUS | 0 |
NCT02516241 | Phase III | Durvalumab + Tremelimumab Carboplatin + Cisplatin + Gemcitabine Durvalumab | Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 14 |
NCT03530397 | Phase I | Carboplatin + Pembrolizumab + Pemetrexed Disodium Durvalumab Carboplatin + MEDI5752 + Pemetrexed Disodium MEDI5752 | A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | ITA | FRA | ESP | AUS | 4 |
NCT02207530 | Phase II | Durvalumab | Phase II Study of MEDI4736 Monotherapy in the Treatment of Patients With Recurrent or Metastatic SCCHN. | Completed | USA | GBR | FRA | ESP | DEU | CAN | BEL | 7 |
NCT02291055 | Phase Ib/II | Durvalumab ADXS11-001 | Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer | Terminated | USA | 0 |
NCT05068232 | Phase II | Carboplatin + Durvalumab + Etoposide Durvalumab | Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) | Recruiting | USA | 0 |
NCT03703297 | Phase III | Durvalumab Durvalumab + Tremelimumab | Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Stage I-III Limited Disease Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) | Active, not recruiting | USA | ITA | GBR | ESP | DEU | CAN | BEL | 12 |
NCT04637594 | Phase III | Durvalumab Nivolumab Atezolizumab Avelumab Pembrolizumab | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy | Active, not recruiting | USA | 0 |
NCT05170204 | Phase III | Durvalumab Alectinib Pralsetinib Entrectinib | A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS | 17 |
NCT04944173 | Phase II | Durvalumab | A Study of Durvalumab and Stereotactic Radiotherapy for Stage I Non-Small Cell Lung Cancer (SCION) | Recruiting | CAN | 0 |
NCT02733042 | Phase Ib/II | Rituximab Durvalumab + Lenalidomide + Rituximab Bendamustine + Durvalumab + Rituximab Durvalumab + Ibrutinib Durvalumab | A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001) | Completed | USA | ITA | GBR | FRA | DEU | 2 |
NCT03007407 | Phase II | Tremelimumab Durvalumab | Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy | Completed | USA | 0 |
NCT02788773 | Phase II | Durvalumab + Tremelimumab Durvalumab | Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer | Active, not recruiting | CAN | 0 |
NCT05128630 | Phase II | Durvalumab | Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC. (DEDALUS) | Recruiting | ITA | 0 |
NCT03875573 | Phase II | Durvalumab Durvalumab + Oleclumab | Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (Neo-CheckRay) | Active, not recruiting | FRA | BEL | 0 |
NCT03840902 | Phase II | Carboplatin + Paclitaxel Bintrafusp alfa Cisplatin + Etoposide Durvalumab Bintrafusp alfa + Cisplatin + Etoposide Bintrafusp alfa + Carboplatin + Paclitaxel Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium | M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) | Terminated | USA | FRA | ESP | DEU | CAN | BEL | AUS | 8 |
NCT03144778 | Phase I | Durvalumab Durvalumab + Tremelimumab | Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO) | Completed | USA | 0 |
NCT02558894 | Phase II | Durvalumab Tremelimumab | Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma | Completed | USA | ESP | DEU | CAN | 2 |
NCT04513925 | Phase III | Atezolizumab + Tiragolumab Durvalumab | A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 16 |
NCT03277482 | Phase I | Durvalumab + Tremelimumab Durvalumab | Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | Terminated | USA | 0 |
NCT02340975 | Phase Ib/II | Durvalumab Tremelimumab | A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma | Completed | USA | CAN | 4 |
NCT04001413 | Phase II | Durvalumab Durvalumab + MEDI0457 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | Withdrawn | USA | 0 |
NCT02616640 | Phase I | Pomalidomide Dexamethasone Durvalumab | A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 1 |
NCT02868632 | Phase I | Tremelimumab Durvalumab + Tremelimumab Durvalumab | Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer | Withdrawn | USA | 0 |
NCT04092283 | Phase III | Carboplatin + Paclitaxel Cisplatin + Etoposide Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Paclitaxel Durvalumab Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium | Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | Active, not recruiting | USA | 1 |
NCT04786093 | Phase II | Durvalumab | Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC | Recruiting | USA | 0 |
NCT04395079 | Phase II | Tremelimumab Durvalumab | Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies | Active, not recruiting | USA | 0 |
NCT06045975 | Phase II | Durvalumab + Tremelimumab Durvalumab | Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation (DUMELEP) | Not yet recruiting | FRA | 0 |
NCT02205333 | Phase Ib/II | Rituximab MEDI6469 Tremelimumab Durvalumab | A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies | Terminated | USA | 0 |
NCT02262741 | Phase I | Tremelimumab Durvalumab | A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer | Completed | USA | CAN | 0 |
NCT05925530 | Phase II | Durvalumab | Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | AUT | 4 |
NCT04385368 | Phase III | Durvalumab | Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1) | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 25 |
NCT02227667 | Phase II | Durvalumab | Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer | Completed | USA | 0 |
NCT04585490 | Phase III | Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab Carboplatin + Durvalumab + Paclitaxel | Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC | Recruiting | USA | 0 |
NCT02352948 | Phase III | Durvalumab Vinorelbine Durvalumab + Tremelimumab Gemcitabine Erlotinib Tremelimumab | A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 17 |
NCT05215106 | Phase II | Durvalumab | Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) (POP-DURVA) | Recruiting | FRA | 0 |
NCT04159974 | Phase II | Durvalumab Durvalumab + Tremelimumab | RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus (RICE) | Recruiting | DEU | 0 |
NCT05043090 | Phase III | Durvalumab + Savolitinib Durvalumab Sunitinib | Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC (SAMETA) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 19 |
NCT03038477 | Phase II | Durvalumab | A Study of Durvalumab in Patients With Borderline Resectable Pancreas Adenocarcinoma Following Neoadjuvant Therapy and Successful Surgical Resection | Withdrawn | USA | 0 |
NCT03237377 | Phase II | Durvalumab + Tremelimumab Durvalumab | Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer | Active, not recruiting | USA | CAN | 0 |
NCT03847649 | Phase II | Durvalumab Durvalumab + Prednisone | Durvalumab Retreatment in Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Toxicity | Recruiting | CAN | 0 |
NCT04866017 | Phase III | Durvalumab BGBA1217 + Tislelizumab Tislelizumab | A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | Terminated | USA | AUS | 2 |
NCT04387084 | Phase I | Durvalumab Pembrolizumab Avelumab Cemiplimab Atezolizumab Nivolumab | Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy | Recruiting | USA | 0 |
NCT03837899 | Phase Ib/II | Durvalumab + Tremelimumab Durvalumab | Durvalumab and Tremelimumab for Pediatric Malignancies | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | 1 |
NCT04003246 | Phase III | Durvalumab | Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02678182 | Phase II | Durvalumab Rucaparib Capecitabine Trastuzumab Capecitabine + Ramucirumab | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial (PLATFORM) | Recruiting | GBR | 0 |
NCT03288532 | Phase III | Durvalumab Durvalumab + Tremelimumab | Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) | Recruiting | GBR | 0 |
NCT03775486 | Phase II | Durvalumab + Olaparib Cisplatin + Durvalumab + Pemetrexed Disodium Durvalumab Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Nab-paclitaxel Cisplatin + Durvalumab + Gemcitabine | Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION) | Active, not recruiting | USA | GBR | BEL | 9 |
NCT03778957 | Phase III | Durvalumab Bevacizumab + Durvalumab | A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1) | Active, not recruiting | USA | ITA | FRA | ESP | CAN | AUS | 12 |
NCT02879617 | Phase II | Durvalumab | A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients | Completed | USA | 0 |
NCT03916419 | Phase II | Durvalumab Carboplatin + Paclitaxel | Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB and IIIA Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT04026412 | Phase III | Nivolumab Ipilimumab + Nivolumab Durvalumab | A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 NSCLC That is Unable or Not Planned to be Removed by Surgery (CheckMate73L) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 18 |
NCT04062708 | Phase II | Cisplatin + Docetaxel + Durvalumab Durvalumab Cisplatin + Durvalumab + Pemetrexed Disodium | CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT05443971 | Phase II | Durvalumab | Durvalumab and Grid Therapy for the Treatment of Non-small Cell Lung Cancer in Patients Who Progressed During or After Treatment With the PACIFIC Regimen | Recruiting | USA | 0 |
NCT05568212 | Phase II | Durvalumab Durvalumab + Olaparib | Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab | Recruiting | ITA | 0 |
NCT05303532 | Phase III | Durvalumab | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab (ROSY-D) | Enrolling by invitation | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 19 |
NCT03601455 | Phase II | Durvalumab + Tremelimumab Durvalumab | Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer | Active, not recruiting | USA | 0 |
NCT04870112 | Phase Ib/II | Carboplatin + Cisplatin + Durvalumab + Etoposide Durvalumab | A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer (SCope-D1) | Terminated | USA | ESP | 2 |
NCT02301130 | Phase I | Mogamulizumab Durvalumab Tremelimumab | Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors | Completed | USA | 0 |
NCT02319044 | Phase II | Durvalumab Tremelimumab | Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck | Completed | USA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 7 |
NCT03741426 | Phase II | Durvalumab Cediranib Durvalumab + Olaparib Cediranib + Olaparib Olaparib | WIRE - Novel Treatments in Renal Cell Cancer (WIRE) | Recruiting | GBR | 0 |
NCT02966587 | Phase II | Durvalumab | Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Withdrawn | USA | 0 |
NCT04602533 | Phase II | Cisplatin + Etoposide Durvalumab | Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN) | Recruiting | DEU | 0 |
NCT02492867 | Phase 0 | Durvalumab Carboplatin + Paclitaxel | A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer | Completed | USA | 0 |
NCT04597671 | Phase III | Durvalumab | Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28) (NVALT28) | Recruiting | 1 | |
NCT02794883 | Phase II | Tremelimumab Durvalumab + Tremelimumab Durvalumab | Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma | Completed | USA | 0 |
NCT03818776 | Phase I | Durvalumab | Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC | Terminated | USA | 0 |
NCT03693300 | Phase II | Durvalumab | A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | Completed | USA | ITA | GBR | FRA | ESP | DEU | 0 |
NCT03141359 | Phase II | Paclitaxel Cisplatin Durvalumab Carboplatin Etoposide | Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC | Active, not recruiting | USA | 0 |
NCT03624231 | Phase II | Durvalumab Durvalumab + Tremelimumab | Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC (DURTRE-RAD) | Completed | DEU | 0 |
NCT02886065 | Phase I | Durvalumab Durvalumab + PVX-410 Durvalumab + Lenalidomide + PVX-410 | A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT02311361 | Phase I | Durvalumab Tremelimumab | Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer | Completed | USA | 0 |
NCT05718297 | Phase II | Brigatinib Durvalumab | Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer (BOUNCE) | Recruiting | ITA | GBR | FRA | ESP | 1 |
NCT02891161 | Phase Ib/II | Durvalumab | Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder | Unknown status | USA | 0 |
NCT02453282 | Phase III | Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Tremelimumab Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 9 |
NCT05696782 | Phase II | Durvalumab | Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer | Recruiting | USA | 0 |
NCT06223711 | Phase II | Durvalumab Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide | Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC | Recruiting | DEU | 0 |
NCT06290505 | Phase II | Durvalumab | A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study (PALEO) | Recruiting | AUS | 1 |
NCT04108026 | Phase II | Durvalumab | Immunotherapy in Patient With Poor General Condition (SAVIMMUNE) | Active, not recruiting | FRA | 0 |
NCT03773666 | Phase I | Durvalumab + Oleclumab Durvalumab | A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) | Completed | USA | 0 |
NCT05757843 | Phase II | Durvalumab | Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab | Recruiting | USA | 0 |
NCT02499328 | Phase Ib/II | Danvatirsen + Durvalumab AZD5069 + Durvalumab Durvalumab Danvatirsen | Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck | Active, not recruiting | USA | ITA | GBR | ESP | DEU | BEL | 0 |
NCT04078152 | FDA approved | Durvalumab | Durvalumab Long-Term Safety and Efficacy Study (WAVE) | Active, not recruiting | USA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 23 |
NCT05221840 | Phase III | Durvalumab + Oleclumab Durvalumab Durvalumab + Monalizumab | A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 14 |
NCT03095274 | Phase II | Durvalumab Tremelimumab | Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE) | Completed | ESP | 0 |
NCT03847428 | Phase III | Durvalumab Bevacizumab + Durvalumab | Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (EMERALD-2) | Active, not recruiting | USA | ITA | FRA | DEU | CAN | AUT | AUS | 17 |
NCT04249362 | Phase II | Durvalumab | Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy (DUART) | Completed | USA | ITA | FRA | ESP | 2 |
NCT03794544 | Phase II | Durvalumab + Oleclumab Danvatirsen + Durvalumab Durvalumab Durvalumab + Monalizumab | Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer | Completed | USA | ITA | FRA | ESP | CAN | 2 |
NCT02179671 | Phase II | Docetaxel + Selumetinib Gefitinib Durvalumab Osimertinib Tremelimumab | Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer | Completed | USA | 0 |
NCT03150836 | Phase II | Durvalumab Durvalumab + Tremelimumab | Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer | Withdrawn | USA | 0 |
NCT05211895 | Phase III | Durvalumab AB154 + Durvalumab | A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 18 |
NCT03618134 | Phase Ib/II | Durvalumab Durvalumab + Tremelimumab | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner | Terminated | USA | 0 |
NCT05617963 | Phase II | Durvalumab | Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax (DURVALUNG) | Recruiting | FRA | 0 |
NCT02454933 | Phase III | Osimertinib Durvalumab | Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours (CAURAL) | Completed | CAN | 2 |
NCT02154490 | Phase II | Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab AZD4547 Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib | Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer | Completed | USA | CAN | 0 |
NCT04748419 | Phase Ib/II | Durvalumab | Safety and Efficacy of Consolidative Hypofractionated Radiation Therapy (hfRT) for Boosting the Residual Primary Lung Cancer With Durvalumab | Recruiting | USA | 0 |
NCT02537418 | Phase I | Cisplatin + Etoposide Durvalumab Tremelimumab | Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens | Active, not recruiting | CAN | 0 |
NCT03801902 | Phase I | Durvalumab + Monalizumab Durvalumab | Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial | Recruiting | USA | 0 |
NCT03102047 | Phase II | Durvalumab | Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer | Completed | USA | 0 |
NCT03026062 | Phase II | Tremelimumab Durvalumab + Tremelimumab Durvalumab | Durvalumab and Tremelimumab in Combo Versus Sequential | Recruiting | USA | 0 |
NCT02639065 | Phase II | Durvalumab | A Study of Durvalumab (MEDI4736) in Esophageal Cancer | Completed | USA | 0 |
NCT04334759 | Phase III | Durvalumab Cisplatin + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium | DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (DREAM3R) | Active, not recruiting | USA | AUS | 1 |
NCT04216290 | Phase II | Cisplatin + Doxorubicin + Methotrexate + Vinblastine Durvalumab + Fluorouracil + Mitomycin C Gemcitabine Fluorouracil + Mitomycin C Durvalumab + Gemcitabine Cisplatin + Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin Durvalumab | A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, the INSPIRE Study | Active, not recruiting | USA | 0 |
NCT03589547 | Phase II | Durvalumab | Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung | Active, not recruiting | USA | 0 |
NCT04585477 | Phase II | Durvalumab | Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) | Recruiting | USA | 0 |
NCT03199040 | Phase I | Durvalumab | Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy | Terminated | USA | 0 |
NCT02549651 | Phase I | Durvalumab + Tremelimumab Durvalumab Danvatirsen + Durvalumab | MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023) | Completed | USA | GBR | FRA | 1 |
NCT06124118 | Phase I | Durvalumab Carboplatin + Paclitaxel | Tumor Treating Fields for Locally Advanced NSCLC (NOVOCURE) | Suspended | USA | 0 |
NCT03015129 | Phase II | Durvalumab Durvalumab + Tremelimumab | A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer | Completed | USA | 0 |
NCT03459846 | Phase II | Durvalumab + Olaparib Durvalumab | A Phase II Study of Durvalumab and Olaparib Compared to Durvalumab in Patients With Advanced, Cisplatin Ineligible Bladder Cancer. (BAYOU) | Active, not recruiting | USA | ESP | CAN | 4 |
NCT04202809 | Phase II | Durvalumab | Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. (ESPADURVA) | Recruiting | DEU | 0 |
NCT04892953 | Phase II | Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Nab-paclitaxel Carboplatin + Durvalumab + Gemcitabine Durvalumab | Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy | Recruiting | USA | 0 |
NCT03056599 | Phase I | Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel | Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma | Completed | USA | 0 |
NCT04238637 | Phase II | Durvalumab Durvalumab + Tremelimumab | Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) | Recruiting | DEU | 0 |
NCT02546661 | Phase I | Danvatirsen + Durvalumab Durvalumab + Selumetinib AZD4547 Durvalumab + Olaparib Durvalumab AZD4547 + Durvalumab Durvalumab + Vistusertib Adavosertib + Durvalumab | Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY) | Active, not recruiting | USA | GBR | FRA | ESP | CAN | 0 |
NCT02866747 | Phase Ib/II | Durvalumab | A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma (STERIMGLI) | Active, not recruiting | FRA | 0 |
NCT04269200 | Phase III | Durvalumab Durvalumab + Olaparib Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Olaparib + Paclitaxel Carboplatin + Paclitaxel | Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E) | Active, not recruiting | USA | ESP | DEU | CAN | BEL | AUS | 16 |
NCT02221960 | Phase I | Durvalumab Efizonerimod | A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors | Completed | USA | AUS | 0 |
NCT04108481 | Phase Ib/II | Durvalumab | Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer (iRE-C) | Suspended | USA | 0 |
NCT04351256 | Phase II | Durvalumab | Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (TRADE-hypo) | Recruiting | DEU | 0 |
NCT02793466 | Phase I | Durvalumab | Durvalumab in Pediatric and Adolescent Patients | Completed | USA | 0 |
NCT04073160 | Phase I | Durvalumab Durvalumab + Tremelimumab | TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer (TRIO Bladder) | Withdrawn | USA | 0 |
NCT03833154 | Phase III | Durvalumab | Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients (PACIFIC-4) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 11 |
NCT02125461 | Phase III | Durvalumab | A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 17 |
NCT03088059 | Phase II | Niraparib Durvalumab + Monalizumab Methotrexate Carboplatin Rogaratinib Mitomycin C Docetaxel Afatinib Paclitaxel Durvalumab Monalizumab Palbociclib Bleomycin Gemcitabine Fluorouracil | Biomarker-based Study in R/M SCCHN (UPSTREAM) | Active, not recruiting | ITA | GBR | FRA | ESP | BEL | 0 |
NCT03618654 | Phase I | Durvalumab + Metformin Durvalumab | Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
NCT03907475 | Phase II | Durvalumab Durvalumab + Nab-paclitaxel Capecitabine + Durvalumab Durvalumab + Pegylated liposomal doxorubicin Durvalumab + Gemcitabine Durvalumab + Paclitaxel Carboplatin + Durvalumab | Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study) | Recruiting | USA | 0 |
NCT03819465 | Phase I | Gemcitabine Durvalumab + Oleclumab Carboplatin Pemetrexed Disodium Nab-paclitaxel Danvatirsen + Durvalumab Cisplatin Durvalumab | A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN) | Active, not recruiting | USA | ESP | BEL | AUT | 5 |
NCT03235869 | Phase I | Durvalumab | Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma | Withdrawn | USA | 0 |
NCT03822351 | Phase II | Durvalumab Durvalumab + Monalizumab Durvalumab + Oleclumab | Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST) | Completed | USA | ITA | FRA | ESP | CAN | 4 |
NCT03784066 | Phase Ib/II | Durvalumab + Tremelimumab Durvalumab | Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity (DUTRELASCO) | Active, not recruiting | BEL | 0 |
NCT03740893 | Phase II | Olaparib Ceralasertib Durvalumab | PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer (PHOENIX) | Recruiting | GBR | 0 |
NCT03084471 | Phase III | Durvalumab + Tremelimumab Durvalumab | An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG) | Completed | USA | ITA | GBR | FRA | DEU | CAN | 2 |
NCT03802747 | Phase I | Durvalumab + Tremelimumab Durvalumab | Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases | Withdrawn | 0 | |
NCT02527434 | Phase II | Durvalumab + Tremelimumab Durvalumab | Study of Tremelimumab in Patients With Advanced Solid Tumors | Completed | USA | BEL | 3 |
NCT02273375 | Phase III | Durvalumab | Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC | Active, not recruiting | USA | ITA | FRA | ESP | CAN | AUS | 13 |
NCT04262869 | Phase II | Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Paclitaxel Durvalumab | Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer | Withdrawn | 0 | |
NCT03610061 | Phase I | Durvalumab | A Trial of Radiotherapy and Durvalumab in DLBCL and FL (RaDD) | Active, not recruiting | AUS | 0 |
NCT03889275 | Phase I | Durvalumab Durvalumab + MEDI5395 MEDI5395 | A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors | Completed | USA | GBR | 0 |
NCT04642469 | Phase III | Durvalumab | Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2) | Completed | USA | ITA | FRA | ESP | CAN | BEL | AUS | 18 |
NCT02551159 | Phase III | Cisplatin Durvalumab Carboplatin + Cetuximab + Fluorouracil Tremelimumab | Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | 14 |
NCT03317158 | Phase Ib/II | Durvalumab BCG solution + Durvalumab | ADAPT-BLADDER: Modern Immunotherpy in BCG-Relapsing Urothelial Carcinoma of the Bladder | Recruiting | USA | 0 |
NCT03635164 | Phase I | Durvalumab | Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT04543110 | Phase II | Durvalumab | Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC (RADIANT) | Recruiting | CAN | 0 |
NCT06083454 | Phase I | Durvalumab Durvalumab + Vitamin C | Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | 0 |
NCT04380636 | Phase III | Carboplatin Pemetrexed Disodium Pembrolizumab Cisplatin Durvalumab Etoposide Olaparib + Pembrolizumab Paclitaxel | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | 19 |
NCT05713838 | Phase II | Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin Durvalumab | Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery | Recruiting | DEU | 0 |
NCT04322643 | Phase II | Durvalumab Pembrolizumab Avelumab Nivolumab Atezolizumab | Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma | Completed | USA | 0 |
NCT02904954 | Phase II | Durvalumab | Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer | Completed | USA | 0 |
NCT03410615 | Phase II | Durvalumab + Tremelimumab Cisplatin Durvalumab | Cisplatin Plus Radiotherapy vs Durvalumab Plus Radiotherapy Followed by Durvalumab vs Durvalumab Plus Radiotherapy Followed by Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Oropharyngeal SCC | Active, not recruiting | ITA | ESP | CAN | BEL | 0 |
NCT02087423 | Phase II | Durvalumab | A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | 9 |
NCT03768570 | Phase II | Durvalumab | Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer | Active, not recruiting | GBR | ESP | CAN | 0 |
NCT03283943 | Phase I | Durvalumab | PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. | Unknown status | CAN | 0 |
NCT03923270 | Phase I | Durvalumab + Tremelimumab Durvalumab Durvalumab + Olaparib | Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03490760 | Phase II | Durvalumab | Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas | Terminated | USA | 0 |
NCT02901548 | Phase II | Durvalumab | Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder | Terminated | USA | 0 |
NCT03164616 | Phase III | Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab Carboplatin + Nab-paclitaxel | Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON) | Active, not recruiting | USA | GBR | DEU | 16 |
NCT02535078 | Phase Ib/II | Durvalumab Tebentafusp Tremelimumab | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma | Completed | USA | 0 |
NCT03999710 | Phase II | Durvalumab | Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02899195 | Phase II | Cisplatin + Durvalumab + Pemetrexed Disodium Durvalumab | Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505) | Completed | USA | 0 |
NCT01993810 | Phase III | Carboplatin + Pemetrexed Disodium Durvalumab Cisplatin + Etoposide Carboplatin + Paclitaxel | Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer | Active, not recruiting | USA | 0 |
NCT02827838 | Phase I | Durvalumab | Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer | Completed | USA | 0 |
NCT02925234 | Phase II | Palbociclib Ribociclib Lenvatinib Ipilimumab + Nivolumab Trametinib Crizotinib Niraparib Selpercatinib Olaparib Erlotinib Erdafitinib Dabrafenib Dacomitinib Rucaparib Axitinib Panitumumab Pemigatinib Durvalumab Afatinib Entrectinib Tepotinib Alpelisib Atezolizumab + Bevacizumab Alectinib Regorafenib Cobimetinib + Vemurafenib Nilotinib Vismodegib Abemaciclib Sunitinib Nivolumab Cabozantinib Lorlatinib Talazoparib Dabrafenib + Trametinib Pembrolizumab Pertuzumab + Trastuzumab | The Drug Rediscovery Protocol (DRUP Trial) (DRUP) | Recruiting | 1 | |
NCT03196401 | Phase I | Durvalumab | A Study of Immunotherapy Plus Radiation Therapy to Stimulate Immunity in Solitary Bone Plasmacytoma | Withdrawn | USA | 0 |
NCT03830866 | Phase III | Durvalumab Cisplatin + Durvalumab Carboplatin + Durvalumab | Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) (CALLA) | Completed | USA | 14 |
NCT03215095 | Phase I | Durvalumab | RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers | Active, not recruiting | USA | 0 |
NCT03245541 | Phase Ib/II | Durvalumab | Study of Durvalumab and Stereotactive Ablative Body Radiotherapy in Advanced Pancreatic Adenocarcinoma (DurvaRad) | Active, not recruiting | USA | 0 |
NCT02336165 | Phase II | Durvalumab Bevacizumab + Durvalumab | Phase 2 Study of MEDI4736 in Patients With Glioblastoma | Completed | USA | AUS | 0 |
NCT04430452 | Phase II | Durvalumab Durvalumab + Tremelimumab | Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition | Recruiting | USA | 0 |
NCT02592551 | Phase II | Durvalumab + Tremelimumab Durvalumab | MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma | Completed | USA | 0 |
NCT04716946 | Phase II | Durvalumab | Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy | Recruiting | USA | 0 |
NCT04364048 | Phase II | Pemetrexed Disodium Durvalumab Paclitaxel Etoposide Docetaxel Carboplatin Cisplatin | Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT05255653 | Phase II | Olaparib Medroxyprogesterone Carboplatin Megestrol acetate Paclitaxel Cisplatin Durvalumab | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) | Recruiting | GBR | FRA | CAN | 1 |
NCT03258554 | Phase II | Cetuximab Durvalumab | Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin | Active, not recruiting | USA | CAN | 0 |
NCT03011814 | Phase Ib/II | Durvalumab Durvalumab + Lenalidomide | Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | Recruiting | USA | 0 |
NCT04470674 | Phase II | Carboplatin + Durvalumab + Pemetrexed Disodium Durvalumab + Pemetrexed Disodium Durvalumab | Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (>=50%) NSCLC Patients | Withdrawn | USA | 0 |
NCT01693562 | Phase Ib/II | Durvalumab | A Phase 1/2 Study to Evaluate MEDI4736 | Completed | USA | ITA | GBR | FRA | DEU | CAN | BEL | 2 |
NCT02669914 | Phase II | Durvalumab | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | Terminated | USA | 0 |
NCT03003962 | Phase III | Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Carboplatin + Paclitaxel | Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) | Active, not recruiting | USA | AUS | 10 |
NCT03975114 | Phase II | Durvalumab + Tremelimumab Durvalumab | A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (MILES-5) | Recruiting | ITA | 0 |
NCT02503774 | Phase I | Durvalumab Oleclumab | MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors | Completed | USA | AUS | 1 |
NCT02519348 | Phase II | Tremelimumab Durvalumab | A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma | Active, not recruiting | USA | ITA | ESP | 6 |
NCT03298451 | Phase III | Sorafenib Durvalumab + Tremelimumab Durvalumab | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 11 |
NCT02369874 | Phase III | Durvalumab + Tremelimumab Durvalumab | Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer | Completed | USA | ITA | FRA | ESP | DEU | BEL | AUS | 17 |
NCT05440864 | Phase II | Durvalumab + Tremelimumab Durvalumab | Durvalumab and Tremelimumab in Resectable HCC ((NEOTOMA)) | Recruiting | ITA | ESP | CAN | 0 |
NCT03206073 | Phase Ib/II | Durvalumab + Tremelimumab Durvalumab | A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer | Completed | USA | 0 |